ASCVD Risk and Statin Use in PAD: Implementing a New Approach to an Old Problem

Marc P Bonaca; Connie N Hess

doi:10.1016/j.jacc.2020.06.009

ASCVD Risk and Statin Use in PAD: Implementing a New Approach to an Old Problem

J Am Coll Cardiol. 2020 Jul 21;76(3):265-267. doi: 10.1016/j.jacc.2020.06.009.

Authors

Marc P Bonaca¹, Connie N Hess²

Affiliations

¹ Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado; CPC Clinical Research, Aurora, Colorado. Electronic address: marc.bonaca@cpcmed.org.
² Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado; CPC Clinical Research, Aurora, Colorado.

PMID: 32674790
DOI: 10.1016/j.jacc.2020.06.009

No abstract available

Keywords: atherosclerosis; cardiovascular disease; cardiovascular events; hydroxymethylglutaryl-CoA reductase inhibitors; peripheral artery disease; secondary prevention.

Publication types

Editorial
Comment

MeSH terms

Atherosclerosis*
Cholesterol, LDL
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Peripheral Arterial Disease*

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors